


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 2120

RESIGNATION OF A SUPERVISOR AND PROPOSED ELECTION OF A NON-EXECUTIVE DIRECTOR

RESIGNATION OF A SUPERVISOR

The supervisory committee (the “**Supervisory Committee**”) of Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”) hereby announces that Mr. XU Yongjiu (“**Mr. Xu**”) has resigned from his position as a supervisor of the Company due to adjustment to work arrangements, with effect from August 14, 2026. Mr. Xu has confirmed that he has no disagreement with the board of directors of the Company (the “**Board**”) or the Supervisory Committee, and there is no matter in relation to his resignation which needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The resignation of Mr. Xu will not affect the normal operation of the Company and the Supervisory Committee.

The Company would like to take this opportunity to express its sincere gratitude to Mr. Xu for his valuable contributions to the Company during his tenure as a supervisor of the Company.

PROPOSED ELECTION OF A NON-EXECUTIVE DIRECTOR

The Company further announces that the nomination of Mr. Xu as a candidate for the position of non-executive director of the Company was considered and approved at the meeting of the Board held on August 14, 2026, with a term commencing from the date of approval at the general meeting of the Company and ending upon the expiry of the term of the fifth session of the Board, and he will be eligible for re-election upon expiry of his term.

The biographical details of Mr. Xu required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) are set out below:

Mr. XU Yongjiu (徐永久), aged 48. Mr. Xu has served as the president, a director and the chairman of the fund investment committee of Shanghai Jinpu Jianfu Equity Investment Management Co., Ltd. (上海金浦健服股權投資管理有限公司) since April 2023, and is fully responsible for the operation and management of the company. He has served as the designated representative of the executive partner of Wenzhou Jinning Equity Investment Partnership (Limited Partnership) (溫州金寧股權投資合夥企業(有限合夥)) since June 2021. From July 2004 to December 2007, he served as a senior investment manager at the Development Research Headquarters of Shanghai International Group. From December 2007 to March 2009, he worked and underwent training at the Asia Pacific Investment Banking Headquarters of Citigroup. From

March 2009 to September 2011, he served as an executive director at Shanghai International Group and the Securities Investment Headquarters of Shanghai International Trust. From October 2011 to October 2015, Mr. Xu served as an executive director of Jinpu Industrial Investment Fund Management Company (金浦產業投資基金管理公司). From April 2016 to March 2023, he served as a director, a member of the investment committee and a senior partner of Shanghai Jinpu Jianfu Equity Investment Management Co., Ltd. (上海金浦健服股權投資管理有限公司), primarily responsible for financial and healthcare investments. From July 2017 to August 2023, he served as a director of Gushengtang Holdings Limited, a company listed on the Stock Exchange (stock code: 2273). From October 2021 to August 2026, he served as a supervisor of the Company, primarily responsible for supervising the daily operation and management of the Company.

Mr. Xu graduated from Southwestern University of Finance and Economics in July 2000 with a bachelor's degree in economics. He graduated from Fudan University in June 2004 with a master's degree in finance. Since January 2015, he has been pursuing postgraduate studies in biotechnology engineering for a master's degree at the School of Life Sciences of Fudan University. He graduated from China Europe International Business School in November 2022 with an EMBA (Executive Master of Business Administration) degree.

As at the date of this announcement, Mr. Xu is deemed to be interested in 4,540,000 domestic shares of the Company by virtue of his interest in a controlled corporation within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The proposed appointment of Mr. Xu is subject to the approval by the shareholders of the Company (the “**Shareholders**”) at the general meeting. If appointed, Mr. Xu will enter into a service contract with the Company. Upon his election, Mr. Xu will not receive any remuneration from the Company in his capacity as a non-executive director.

Save as disclosed above, Mr. Xu does not hold any other positions with the Company or its subsidiaries as at the date of this announcement. Mr. Xu did not hold any other directorship in any public companies listed on any securities market in Hong Kong and/or overseas in the past three years. He does not hold any other major appointments or professional qualifications, nor does he have any relationship with any directors, supervisors, senior management of the Company or substantial or controlling shareholders of the Company.

As at the date of this announcement, save as disclosed above, Mr. Xu does not have any interest in the shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Xu has never been subject to any penalty imposed by the China Securities Regulatory Commission or other relevant securities regulatory authorities or stock exchanges.

Save as disclosed above, the Board is not aware of any other information to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules or any other matter in relation to Mr. Xu that needs to be brought to the attention of the Shareholders.

The Company will convene an extraordinary general meeting to approve the proposed election of a non-executive director. A circular and notice containing, among others, details of the proposed election of a non-executive director are expected to be dispatched to the Shareholders as soon as reasonably practicable in accordance with the means of receiving corporate communications selected by the Shareholders.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC
August 14, 2026

As at the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. SZETO Wing Fu.